BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis, and structure-activity relationship of novel RIPK2 inhibitors. 2022

Shuwei Wu, and Liben Xu, and Xinhui Wang, and Qing Yang, and Jingrui Wang, and Sudan He, and Xiaohu Zhang
Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, China.

The NOD1/2 (nucleotide-binding oligomerization domain-containing protein 1/2) signaling pathways are involved in innate immune control and host defense. NOD dysfunction can result in a variety of autoimmune disorders. NOD-induced generation of inflammatory cytokines is mediated by receptor-interacting protein kinase 2 (RIPK2), which has been considered as a promising therapeutic target. Herein, we disclose the design, synthesis, and SAR study of a series of RIPK2 inhibitors. The lead compound 17 displayed a high affinity for RIPK2 (Kd = 5.9 nM) and was capable of inhibiting RIPK2 kinase function in an ADP-Glo assay. In vitro DMPK studies showed that compound 17 had good metabolic stability and no CYP inhibition. Compound 17 effectively suppressed inflammatory cytokine production in both cells and animal model.

UI MeSH Term Description Entries
D007472 Iohexol An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. Compound 545,Exypaque,Iohexol 350,Nycodenz,Omnipaque
D000244 Adenosine Diphosphate Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position. ADP,Adenosine Pyrophosphate,Magnesium ADP,MgADP,Adenosine 5'-Pyrophosphate,5'-Pyrophosphate, Adenosine,ADP, Magnesium,Adenosine 5' Pyrophosphate,Diphosphate, Adenosine,Pyrophosphate, Adenosine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D016207 Cytokines Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. Cytokine

Related Publications

Shuwei Wu, and Liben Xu, and Xinhui Wang, and Qing Yang, and Jingrui Wang, and Sudan He, and Xiaohu Zhang
Design, synthesis, structure-activity relationship studies, and evaluation of novel GLS1 inhibitors.
May 2023, Bioorganic & medicinal chemistry letters,
Shuwei Wu, and Liben Xu, and Xinhui Wang, and Qing Yang, and Jingrui Wang, and Sudan He, and Xiaohu Zhang
Novel bis-arylalkylamines as myeloperoxidase inhibitors: Design, synthesis, and structure-activity relationship study.
November 2016, European journal of medicinal chemistry,
Shuwei Wu, and Liben Xu, and Xinhui Wang, and Qing Yang, and Jingrui Wang, and Sudan He, and Xiaohu Zhang
Structure-based design, synthesis, and structure-activity relationship studies of novel non-nucleoside adenosine deaminase inhibitors.
July 2004, Journal of medicinal chemistry,
Shuwei Wu, and Liben Xu, and Xinhui Wang, and Qing Yang, and Jingrui Wang, and Sudan He, and Xiaohu Zhang
Diacylhydrazine derivatives as novel potential chitin biosynthesis inhibitors: design, synthesis, and structure-activity relationship.
July 2009, European journal of medicinal chemistry,
Shuwei Wu, and Liben Xu, and Xinhui Wang, and Qing Yang, and Jingrui Wang, and Sudan He, and Xiaohu Zhang
Design, synthesis and structure-activity relationship of novel Relacin analogs as inhibitors of Rel proteins.
January 2013, European journal of medicinal chemistry,
Shuwei Wu, and Liben Xu, and Xinhui Wang, and Qing Yang, and Jingrui Wang, and Sudan He, and Xiaohu Zhang
Design, synthesis and structure-activity relationship of dihydrobenzoquinolines as novel inhibitors against influenza A virus.
December 2022, European journal of medicinal chemistry,
Shuwei Wu, and Liben Xu, and Xinhui Wang, and Qing Yang, and Jingrui Wang, and Sudan He, and Xiaohu Zhang
Design, synthesis and structure-activity relationship of novel inhibitors against H5N1 hemagglutinin-mediated membrane fusion.
November 2012, European journal of medicinal chemistry,
Shuwei Wu, and Liben Xu, and Xinhui Wang, and Qing Yang, and Jingrui Wang, and Sudan He, and Xiaohu Zhang
Design, synthesis and structure-activity relationship of novel diphenylamine derivatives.
February 2016, Bioorganic & medicinal chemistry,
Shuwei Wu, and Liben Xu, and Xinhui Wang, and Qing Yang, and Jingrui Wang, and Sudan He, and Xiaohu Zhang
Design, synthesis and structure-activity relationship of novel coumarin derivatives.
June 2011, Pest management science,
Shuwei Wu, and Liben Xu, and Xinhui Wang, and Qing Yang, and Jingrui Wang, and Sudan He, and Xiaohu Zhang
Design, synthesis, and structure-activity relationship of novel CCR2 antagonists.
March 2009, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!